The city of San Antonio, Texas, currently has 18 active clinical trials seeking participants for Asthma research studies.
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
NCT06307665
Recruiting
The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
05/22/2024
Locations: Research Site, San Antonio, Texas
Conditions: Asthma
Register for Updates
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
NCT04718389
Recruiting
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all participants will continue their non-biologic Baseline standard of care (SoC) asthma treatment.
Gender:
All
Ages:
12 years and above
Trial Updated:
04/29/2024
Locations: GSK Investigational Site, San Antonio, Texas +3 locations
Conditions: Asthma
Register for Updates
Dupilumab Effects Against Aeroallergen Challenge
NCT05720325
Recruiting
The trial involves two interventions: (i) exposure to HDM in the ACC and (ii) administration of dupilumab/placebo for dupilumab.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/05/2024
Locations: Biogenics Research Chamber, San Antonio, Texas +1 locations
Conditions: Asthma, Allergic
Register for Updates
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
NCT05748600
Recruiting
The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.
Gender:
All
Ages:
Between 12 years and 99 years
Trial Updated:
02/09/2024
Locations: Research Site 40001-377, San Antonio, Texas
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack
Register for Updates
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
NCT05813288
Recruiting
The objective of this clinical study is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma.
Gender:
All
Ages:
Between 12 years and 99 years
Trial Updated:
02/09/2024
Locations: Research Site 30001-238, San Antonio, Texas +1 locations
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Register for Updates
An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
NCT05243680
Recruiting
The purpose of this open-label 12-month extension study is to continue to characterize the long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic phenotype following completion of clinical studies 206713 or 213744.
Gender:
All
Ages:
12 years and above
Trial Updated:
10/13/2023
Locations: GSK Investigational Site, San Antonio, Texas
Conditions: Asthma
Register for Updates